Clinical Trials · NCT00690898

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

Name: Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Lanreotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 108
Start date: May 2008
Locations: 27 sites, 9 countries
Primary endpoint: Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)

View Lanreotide compound reference